Genprex, Inc.

Equities

GNPX

US3724462037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
2.44 ^USD	+3.39%		+10.41%	-73.48%

Apr. 03	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	CI
Apr. 02	Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	CI

Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 01, 2024 at 05:25 pm EDT

Genprex, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 30.86 million compared to USD 23.74 million a year ago. Basic loss per share from continuing operations was USD 22.56 compared to USD 19.8 a year ago.

Latest news about Genprex, Inc.

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer	Apr. 03	CI
Genprex, Inc. Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System	Apr. 02	CI
Genprex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target	Mar. 25	MT
Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants	Mar. 22	MT
Genprex Launches $6.5 Million Securities Offering; Shares Fall	Mar. 19	MT
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers	Mar. 12	MT
Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	Mar. 12	CI
Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	Feb. 07	CI
Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer	Feb. 05	CI
Genprex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Investors Weigh -2-	Nov. 10	DJ
Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics	23-10-04	CI
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs	23-08-22	CI
Genprex, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Genprex's Small-Cell Lung Cancer Treatment Gets FDA Orphan Drug Designation; Shares Rise	23-08-10	MT
Genprex Closes $7.5 Million Offering	23-07-21	MT
Genprex to Raise $7.5 Million From Registered Direct Offering; Shares Slip	23-07-19	MT
Genprex Licenses Diabetes Gene Therapy From University of Pittsburgh	23-07-18	MT
GENPREX SHARES RISE 4.1% AFTER CO ENTERS INTO EXCLUSIVE LICENSE…	23-07-18	RE
Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate	23-07-11	CI
Genprex Receives Chinese Patent for Cancer Drug Candidate Reqorsa in Combination with PD1 Antibodies	23-07-05	MT
Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers	23-07-05	CI
Genprex Says US FDA Granted Fast Track Designation For Reqorsa, Tecentriq Combination Therapy for Lung Cancer	23-06-28	MT

Chart Genprex, Inc.

Duration

Period

More charts

Company Profile

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - American Society of Gene & Cell Therapy Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.44 USD

Average target price

165 USD

Spread / Average Target

+6,662.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENPREX, INC.	-73.48%	5.12M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+5.01%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-6.73%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B
VIKING THERAPEUTICS, INC.	+313.59%	8.49B

Bio Therapeutic Drugs